Glaukos: iDose Breakthrough Fuels Volume Rally After Forecast Upgrade
Reading Time: 3 minutes
The massive revenue jump in Q1 2026 of 41% confirms market acceptance of the iDose TR implant and triggers large-scale institutional purchases. With the raised annual forecast of up to $635 million, the fundamental shift toward profitability for the medical technology specialist is within reach. The expansion of US reimbursement guidelines and the strong pipeline in the corneal therapy sector offer sustainable potential for long-term market dominance. Glaukos has established itself as the undisputed pioneer in minimally invasive glaucoma...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
